INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024 instead of 31 May 2023 Parties also currently negotiating a potential renegotiation. | May 29, 2023
INSIDE INFORMATION Potential license agreement to produce and commercialize original and transformed ALLOB cells BioSenic to potentially receive royalty.
BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights. Strengthening of Executive Committee and Board of Directors with the .
REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in July/August 2023Ongoing discussions for key partnerships with lead clinical assets Mont-Saint-Guibert, Belgium, May 22nd,. | May 22, 2023